3Giampietro O,Matteucci E,Pedrinelli R.Erythrocyte sodium-hydrogen exchange and microalbuminuria in type I diabetes[J].Diabetes Care,1996,19(9):995-997.
2Wong PC, Hart SD,Zaspel AM, et al. Functional studies of nonpeptide angiotensin Ⅱ receptor studype-specific ligands: Dup753 (A Ⅱ-1 ) and PD123177 (AⅡ-2). J Pharmacol Exp Ther, 1990,255 (2): 584-592.
3Christen Y, Waeber B, Nussberger J, et al. Oral administration of Dup753, a specific angiotensin Ⅱ receptor antagonist, to normal male volunteers. Circulation, 1991,83(4) :1333-1346.
4Gansevoort RT, de Zeeuw D, Shahinfar S, et al. Effects of the angiotensin Ⅱ losartan in hypertensive patients with renal disease. J Hypertens, 1994,12 ( Suppl ): 37 -42.
5元柏民.心血管病诊断标准.北京:学苑出版社,1992.178-181.
6Obeta J, Nakamura T, Kuroyanagi R, et al. Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats. Kidney Int, 1997, 52(suppl)63:29-231.
7Hartland A, Gosling P. Microalbuminuria: yet another cardiovascular risk factor?[J].Ann Clin Biochem, 1999, 36:700-703.
8Alderman MH, Cohen H, Madhavan S. Epidemiology of risk in hypertensive: experience in treated patients[J]. Am J Hypertens, 1998, 11:874-876.
9Bianchi S, Bigazzi R, Campese MV. Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications[J]. Am J Kidney Dis, 1999, 34:976-995.
10Egido J. Vasoactive hormones and renal sclerosis[J]. Kidney Int, 1996, 49:578-582.
